Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM, O'Brien S. Gallipoli P, et al. Among authors: clark re. Br J Haematol. 2022 Mar;196(6):e55-e57. doi: 10.1111/bjh.17961. Epub 2022 Jan 6. Br J Haematol. 2022. PMID: 34993961 Free PMC article. No abstract available.
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M. Clark RE, et al. Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26. Lancet Haematol. 2017. PMID: 28566209 Free article. Clinical Trial.
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
Austin GM, Knight K, Bell J, Carter A, Heartin E, Watson D, Foroni L, Christmas SE, Polydoros F, Clark RE. Austin GM, et al. Among authors: clark re. Br J Haematol. 2019 May;185(4):791-793. doi: 10.1111/bjh.15629. Epub 2018 Nov 8. Br J Haematol. 2019. PMID: 30408160 Free article. Clinical Trial. No abstract available.
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M. Clark RE, et al. Lancet Haematol. 2019 Jul;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8. Epub 2019 Jun 12. Lancet Haematol. 2019. PMID: 31201085 Free article. Clinical Trial.
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Milojkovic D, Cross NCP, Ali S, Byrne J, Campbell G, Dignan FL, Drummond M, Huntly B, Marshall S, McMullin MF, Neelakantan P, Raghavan M, Sivakumaran M, Tighe J, Wandroo F, Willis F, Glen F, Fildes L, Collington SJ, Ryan J, Clark RE, Mead AJ. Milojkovic D, et al. Among authors: clark re. Br J Haematol. 2021 Jan;192(1):62-74. doi: 10.1111/bjh.16733. Epub 2020 May 24. Br J Haematol. 2021. PMID: 32449159 Free article.
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Claudiani S, Janssen JJWM, Byrne J, Smith G, Blijlevens N, Raghavan M, Smith M, Clark RE, Mclain-Smith S, Carter AM, Milojkovic D, Apperley JF. Claudiani S, et al. Among authors: clark re. Eur J Haematol. 2022 Jul;109(1):90-99. doi: 10.1111/ejh.13775. Epub 2022 May 17. Eur J Haematol. 2022. PMID: 35403752 Free PMC article.
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.
Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valgañon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Foroni L. Grinfeld J, et al. Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10. Br J Haematol. 2013. PMID: 24117365 Free article.
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. Marin D, et al. Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844874
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL, Copland M. Horne GA, et al. Among authors: clark re. Leukemia. 2020 Jul;34(7):1775-1786. doi: 10.1038/s41375-019-0700-9. Epub 2020 Jan 10. Leukemia. 2020. PMID: 31925317 Free PMC article. Clinical Trial.
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.
Olavarria E, Reiffers J, Boque C, Sureda A, Meloni G, Michallet M, Clark RE, Blaise D, Carella AM, Cahn JY, Jouet JP, Rizzoli V, Van Biezen A, Gratwohl A, Goldman JM, Niederwieser D, Apperley JF. Olavarria E, et al. Among authors: clark re. Br J Haematol. 2002 Sep;118(3):762-70. doi: 10.1046/j.1365-2141.2002.03600.x. Br J Haematol. 2002. PMID: 12181043 Free article.
738 results